Can the hair follicle become a model for studying selected aspects of human ocular immune privilege?

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 7, 2011, Pages 4447-4458

  Kinori, Michael ^a,b   Kloepper, Jennifer E ^b   Paus, Ralf ^b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; BETA 2 MICROGLOBULIN; FAS LIGAND; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; BIOLOGICAL MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DOWN REGULATION; GRAFT REJECTION; HAIR FOLLICLE; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; LANGERHANS CELL; NATURAL KILLER T CELL; NONHUMAN; ORGAN CULTURE; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; STEM CELL; VISUAL SYSTEM; ANIMAL; CYTOLOGY; EYE; EYE DISEASE; IMMUNOLOGY; PATHOLOGY; REVIEW;

ANIMALS; AUTOIMMUNITY; EYE; EYE DISEASES; HAIR FOLLICLE; HUMANS; MODELS, BIOLOGICAL;

EID: 80052378504     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-7154     Document Type: Article

References (176)

1. Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29: 58-69.
2. van Dooremaal J. Die Entwicklung der in fremden Grund versetzten lebenden Geweba. Graefes Arch Ophthalmol. 1873;19:358-373.
3. Hazlett LD, Hendricks RL. Reviews for immune privilege in the year 2010: immune privilege and infection. Ocul Immunol Inflamm. 2010;18:237-243.
4. McKenna KC, Chen PW. Influence of immune privilege on ocular tumor development. Ocul Immunol Inflamm. 2010;18:80-90.
5. Taylor AW. Ocular immune privilege. Eye (Lond). 2009;23:1885-1889.
6. Niederkorn JY. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res. 2009;28:329-347.
7. Niederkorn JY, Stein-Streilein J. History and physiology of immune privilege. Ocul Immunol Inflamm. 2010;18:19-23.
8. Hori J, Vega JL, Masli S. Review of ocular immune privilege in the year 2010: modifying the immune privilege of the eye. Ocul Immunol Inflamm. 2010;18:325-333.
9. Forrester JV. Privilege revisited: an evaluation of the eye's defence mechanisms. Eye (Lond). 2009;23:756-766.
10. Niederkorn JY. High-risk corneal allografts and why they lose their immune privilege. Curr Opin Allergy Clin Immunol. 2010;10:493-497.
11. Forrester JV, Xu H, Lambe T, Cornall R. Immune privilege or privileged immunity? Mucosal Immunol. 2008;1:372-381.
12. Cobbold SP. Future therapeutics for the induction of peripheral immune tolerance in autoimmune disease and organ transplantation. Immunotherapy. 2009;1:447-460.
13. Cunnusamy K, Chen PW, Niederkorn JY. Paradigm shifts in the role of CD4+ T cells in keratoplasty. Discov Med. 2010;10:452-461.
14. Caspi RR. Ocular autoimmunity: the price of privilege? Immunol Rev. 2006;213:23-35.
15. Masli S, Vega JL. Ocular immune privilege sites. Methods Mol Biol. 2011;677:449-458.
16. Hori J, Taniguchi H, Wang M, Oshima M, Azuma M. GITR ligandmediated local expansion of regulatory T cells contributes to immune privilege of corneal allografts. Invest Ophthalmol Vis Sci. 2010;51:6556-6565.
17. Cunnusamy K, Chen PW, Niederkorn JY. IL-17 promotes immune privilege of corneal allografts. J Immunol. 2010;185:4651-4658.
18. Qiao H, Lucas K, Stein-Streilein J. Retinal laser burn disrupts immune privilege in the eye. Am J Pathol. 2009;174:414-422.
19. Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci. 2006;47:3912-3918.
20. Hori J, Wang M, Miyashita M, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol. 2006;177:5928-5935.
21. Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW. Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci. 2005;46:908-919.
22. Sonoda KH, Sakamoto T, Qiao H, et al. The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation. Immunology. 2005;116:390-399.
23. Taylor AW, Yee DG. Somatostatin is an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 2003;44:2644-2649.
24. Streilein JW, Arancibia-Caracamo C, Osawa H. The role of minor histocompatibility alloantigens in penetrating keratoplasty. Dev Ophthalmol. 2003;36:74-88.
25. Lee HO, Herndon JM, Barreiro R, Griffith TS, Ferguson TA. TRAIL: a mechanism of tumor surveillance in an immune privileged site. J Immunol. 2002;169:4739-4744.
26. Kawanaka N, Taylor AW. Localized retinal neuropeptide regulation of macrophage and microglial cell functionality. J Neuroimmunol. 2011;232:17-25.
27. Murphy K, Travers P, Walport M. Janeway's Immunobiology. 7th ed. New York: Garland Science Press; 2008;711-729.
28. Eichhorn M, Horneber M, Streilein JW, Lütjen-Drecoll E. Anterior chamber-associated immune deviation elicited via primate eyes. Invest Ophthalmol Vis Sci. 1993;34:2926-2930.
29. Usui Y, Okunuki Y, Hattori T, et al. Functional expression of B7H1 on retinal pigment epithelial cells. Exp Eye Res. 2008;86: 52-59.
30. Ryu YH, Kim JC. Expression of indoleamine 2,3-dioxygenase in human corneal cells as a local immunosuppressive factor. Invest Ophthalmol Vis Sci. 2007;48:4148-4152.
31. Sugita S, Keino H, Futagami Y, et al. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells. Invest Ophthalmol Vis Sci. 2006;47:5376-5384.
32. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest Ophthalmol Vis Sci. 2000;41: 4195-4202.
33. Yang W, Li H, Chen PW, et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci. 2009;50:273-280.
34. Paus R, Nickoloff BJ, Ito T. A 'hairy' privilege. Trends Immunol. 2005;26:32-40.
35. Huang L, Baban B, Johnson BA, 3rd, Mellor AL. Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol. 2010;29:133-155.
36. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol. 1977;25:1-54.
37. Erlebacher A. Why isn't the fetus rejected? Curr Opin Immunol. 2001;13:590-593.
38. Mellor AL, Munn DH. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol. 2000;18:367-391.
39. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3:879-889.
40. Meinhardt A, Hedger MP. Immunological, paracrine and endocrine aspects of testicular immune privilege. Mol Cell Endocrinol. 2011;335:60-68.
41. Ito T, Ito N, Saathoff M, et al. Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol. 2005;125:1139-1148.
42. Schneider MR, Schmidt-Ullrich R, Paus R. The hair follicle as a dynamic miniorgan. Curr Biol. 2009;19:R132-R142.
43. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007;117:2019-2027.
44. Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol. 2004;164:623-634.
45. Peters EM, Liotiri S, Bodo E, et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol. 2007;171:1872-1886.
46. Kaplan HJ, Niederkorn JY. Regional immunity and immune privilege. Chem Immunol Allergy. 2007;92:11-26.
47. Niederkorn JY, Wang S. Immune privilege of the eye and fetus: parallel universes? Transplantation. 2005;80:1139-1144.
48. Arck PC, Gilhar A, Bienenstock J, Paus R. The alchemy of immune privilege explored from a neuroimmunological perspective. Curr Opin Pharmacol. 2008;8:480-489.
49. Niederkorn JY. Mechanisms of immune privilege in the eye and hair follicle. J Investig Dermatol Symp Proc. 2003;8:168-172.
50. Simpson E. A historical perspective on immunological privilege. Immunol Rev. 2006;213:12-22.
51. Welge-Lussen U, Wilsch C, Neuhardt T, Wayne Streilein J, Lütjen-Drecoll E. Loss of anterior chamber-associated immune deviation (ACAID) in aged retinal degeneration (rd) mice. Invest Ophthalmol Vis Sci. 1999;40:3209-3214.
52. Billingham RE. Transplantation immunity evoked by skin homografts and expressed in intact skin. Adv Biol Skin. 1971;11: 183-198.
53. Billingham RE, Silvers WK. A biologist's reflections on dermatology. J Invest Dermatol. 1971;57:227-240.
54. Anand V, Duffy B, Yang Z, Dejneka NS, Maguire AM, Bennett J. A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol Ther. 2002;5:125-132.
55. Wenkel H, Chen PW, Ksander BR, Streilein JW. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space. Invest Ophthalmol Vis Sci. 1999;40:3202-3208.
56. Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J Investig Dermatol Symp Proc. 2003;8:188-194.
57. Meyer KC, Klatte JE, Dinh HV, et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol. 2008;159:1077-1085.
58. Niederkorn JY. Role of NKT cells in anterior chamber-associated immune deviation. Expert Rev Clin Immunol. 2009;5:137-144.
59. Hori J. Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation. J Ocul Biol Dis Infor. 2008;1:94-100.
60. Taylor AW, Streilein JW, Cousins SW. Identification of alphamelanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res. 1992;11:1199-1206.
61. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 1991;32: 2201-2211.
62. Denniston AK, Kottoor SH, Khan I, et al. Endogenous cortisol and TGF-β in human aqueous humor contribute to ocular immune privilege by regulating dendritic cell function. J Immunol. 2011;186:305-311.
63. Granstein RD, Staszewski R, Knisely TL, et al. Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation. J Immunol. 1990;144:3021-3027.
64. Sheibani N, Sorenson CM, Cornelius LA, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun. 2000;267:257-261.
65. Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol. 1994;153:1080-1086.
66. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160:5693-5696.
67. Taylor AW, Yee DG, Streilein JW. Suppression of nitric oxide generated by inflammatory macrophages by calcitonin gene-related peptide in aqueous humor. Invest Ophthalmol Vis Sci. 1998;39:1372-1378.
68. Kennedy MC, Rosenbaum JT, Brown J, et al. Novel production of interleukin-1 receptor antagonist peptides in normal human cornea. J Clin Invest. 1995;95:82-88.
69. Sugita S, Streilein JW. Iris pigment epithelium expressing CD86 (B7-2) directly suppresses T cell activation in vitro via binding to cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2003;198:161-171.
70. Ito N, Ito T, Kromminga A, et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. Faseb J. 2005;19:1332-1334.
71. Ito T, Ito N, Saatoff M, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128:1196-1206.
72. Velasco P, Huegel R, Brasch J, et al. The angiogenesis inhibitor thrombospondin-1 inhibits acute cutaneous hypersensitivity reactions. J Invest Dermatol. 2009;129:2022-2030.
73. Kim CY, Masli S, Streilein JW. Qa-1, a nonclassical MHC molecule with immunomodulatory functions, is ubiquitously expressed in the immune-privileged anterior chamber of the eye. Ocul Immunol Inflamm. 2005;13:271-277.
74. Streilein JW, Toews GB, Bergstresser PR. Corneal allografts fail to express Ia antigens. Nature. 1979;282:326-327.
75. Niederkorn JY, Chiang EY, Ungchusri T, Stroynowski I. Expression of a nonclassical MHC class Ib molecule in the eye. Transplantation. 1999;68:1790-1799.
76. Wang HM, Kaplan HJ, Chan WC, Johnson M. The distribution and ontogeny of MHC antigens in murine ocular tissue. Invest Ophthalmol Vis Sci. 1987;28:1383-1389.
77. Paus R, Eichmuller S, Hofmann U, Czarnetzki BM, Robinson P. Expression of classical and non-classical MHC class I antigens in murine hair follicles. Br J Dermatol. 1994;131:177-183.
78. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
79. Sugita S, Taguchi C, Takase H, et al. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis. Br J Ophthalmol. 2000;84:1130-1134.
80. Kang H, Wu WY, Lo BK, et al. Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol. 2010;130: 2677-2680.
81. Streilein JW, Niederkorn JY. Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med. 1981;153:1058-1067.
82. Jones TB, Kaplan AM. Immunologic tolerance to HGG in mice. I. Suppression of the HGG response in normal mice with spleen cells or a spleen cell lysate from tolerant mice. J Immunol. 1977;118:1880-1885.
83. Kaplan HJ, Streilein JW, Stevens TR. Transplantation immunology of the anterior chamber of the eye. II. Immune response to allogeneic cells. J Immunol. 1975;115:805-810.
84. Streilein JW, Dana MR, Ksander BR. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol Today. 1997;18:443-449.
85. Wilbanks GA, Streilein JW. Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen; evidence of two functionally and phenotypically distinct T-suppressor cell populations. Immunology. 1990;71:383-389.
86. Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol. 1992;22:165-173.
87. Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev. 2006;213:213-227.
88. Wilbanks GA, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J Immunol. 1991;146:2610-2617.
89. Crawford K, Kaufman PL, Gabelt BT. Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res. 1987;6:1035-1044.
90. Faunce DE, Sonoda KH, Stein-Streilein J. MIP-2 recruits NKT cells to the spleen during tolerance induction. J Immunol. 2001;166: 313-321.
91. Faunce DE, Stein-Streilein J. NKT cell-derived RANTES recruits APCs and CD8+ T cells to the spleen during the generation of regulatory T cells in tolerance. J Immunol. 2002;169:31-38.
92. Sonoda KH, Faunce DE, Taniguchi M, Exley M, Balk S, Stein-Streilein J. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol. 2001;166:42-50.
93. Nakamura T, Sonoda KH, Faunce DE, et al. CD4+ NKT cells, but not conventional CD4+ T cells, are required to generate efferent CD8+ T regulatory cells following antigen inoculation in an immune-privileged site. J Immunol. 2003;171:1266-1271.
94. Skelsey ME, Mayhew E, Niederkorn JY. CD25+, interleukin-10-producing CD4+ T cells are required for suppressor cell production and immune privilege in the anterior chamber of the eye. Immunology. 2003;110:18-29.
95. Wang Y, Goldschneider I, O'Rourke J, Cone RE. Blood mononuclear cells induce regulatory NK T thymocytes in anterior chamber-associated immune deviation. J Leukoc Biol. 2001;69:741-746.
96. Li X, Taylor S, Zegarelli B, Shen S, O'Rourke J, Cone RE. The induction of splenic suppressor T cells through an immuneprivileged site requires an intact sympathetic nervous system. J Neuroimmunol. 2004; 153:40-49.
97. Lütjen-Drecoll E, Bergstrom A, Ehinger B. Ultrastructure of retinal cells transplanted to the rabbit choroid. Ophthalmologica. 2000;214:70-77.
98. Streilein JW. Immune regulation and the eye: a dangerous compromise. FASEB J. 1987;1:199-208.
99. Streilein JW. Ocular immune privilege and the Faustian dilemma. The Proctor lecture. Invest Ophthalmol Vis Sci. 1996;37:1940-1950.
100. Kezuka T, Sakai J, Usui N, Streilein JW, Usui M. Evidence for antigen-specific immune deviation in patients with acute retinal necrosis. Arch Ophthalmol. 2001;119:1044-1049.
101. Streilein JW, Okamoto S, Sano Y, Taylor AW. Neural control of ocular immune privilege. Ann N Y Acad Sci. 2000;917:297-306.
102. Sugita S, Futagami Y, Smith SB, Naggar H, Mochizuki M. Retinal and ciliary body pigment epithelium suppress activation of T lymphocytes via transforming growth factor beta. Exp Eye Res. 2006;83:1459-1471.
103. Streilein JW, Ma N, Wenkel H, Ng TF, Zamiri P. Immunobiology and privilege of neuronal retina and pigment epithelium transplants. Vision Res. 2002;42:487-495.
104. Jorgensen A, Wiencke AK, la Cour M, et al. Human retinal pigment epithelial cell-induced apoptosis in activated T cells. Invest Ophthalmol Vis Sci. 1998;39:1590-1599.
105. Wenkel H, Streilein JW. Evidence that retinal pigment epithelium functions as an immune-privileged tissue. Invest Ophthalmol Vis Sci. 2000;41:3467-3473.
106. Ng TF, Osawa H, Hori J, Young MJ, Streilein JW. Allogeneic neonatal neuronal retina grafts display partial immune privilege in the subcapsular space of the kidney. J Immunol. 2002;169: 5601-5606.
107. Jiang LQ, Jorquera M, Streilein JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci. 1993;34:3347-3354.
108. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006;7:354-359.
109. The Collaborative Corneal Transplantation Studies Research Group. The collaborative corneal transplantation studies: effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110:1392-1403.
110. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54:694-704.
111. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8:74-80.
112. Roychoudhury J, Herndon JM, Yin J, Apte RS, Ferguson TA. Targeting immune privilege to prevent pathogenic neovascularization. Invest Ophthalmol Vis Sci. 2010;51:3560-3566.
113. Paus R, Christoph T, Muller-Rover S. Immunology of the hair follicle: a short journey into terra incognita. J Investig Dermatol Symp Proc. 1999;4:226-234.
114. Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466:113-117.
115. Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ. 2010;341:c3671.
116. Gilhar A. Collapse of immune privilege in alopecia areata: coincidental or substantial? J Invest Dermatol. 2010;130:2535-2537.
117. Harries MJ, Paus R. The pathogenesis of primary cicatricial alopecias. Am J Pathol. 2010;177:2152-2162.
118. Harrist TJ, Ruiter DJ, Mihm MC Jr, Bhan AK. Distribution of major histocompatibility antigens in normal skin. Br J Dermatol. 1983;109:623-633.
119. Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A. 1998;95:5199-5204.
120. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213: 48-65.
121. Foulds LM, Boysen RI, Crane M, et al. Molecular identification of lyso-glycerophosphocholines as endogenous immunosuppressives in bovine and rat gonadal fluids. Biol Reprod. 2008;79:525-536.
122. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999;341:491-497.
123. Christoph T, Muller-Rover S, Audring H, et al. The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol. 2000;142:862-873.
124. Gilliam AC, Kremer IB, Yoshida Y, et al. The human hair follicle: a reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure. J Invest Dermatol. 1998;110: 422-427.
125. Kaufman G, d'Ovidio R, Kaldawy A, et al. An unexpected twist in alopecia areata pathogenesis: are NK cells protective and CD49b+ T cells pathogenic? Exp Dermatol. 2010;19:e347-349.
126. Gilhar A, Shalaginov R, Assy B, Serafimovich S, Kalish RS. Alopecia areata is a T-lymphocyte mediated autoimmune disease: lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice. J Investig Dermatol Symp Proc. 1999;4:207-210.
127. Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish RS. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest. 1998;101:62-67.
128. McElwee KJ, Yu M, Park SW, Ross EK, Finner A, Shapiro J. What can we learn from animal models of Alopecia areata? Dermatology. 2005;211:47-53.
129. Ito T, Hashizume H, Takigawa M. Significant increase of MAGE 3 specific-CTLs in alopecia areata patients. Presented at the 6th World Congress for Hair Research. Cairns, Australia; 2010.
130. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol. 2001;117:1357-1362.
131. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med. 1993;66:541-554.
132. Yokoyama WM, Kim S. Licensing of natural killer cells by selfmajor histocompatibility complex class I. Immunol Rev. 2006;214:143-154.
133. Vivier E. What is natural in natural killer cells? Immunol Lett. 2006;107:1-7.
134. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev. 2006;214:186-201.
135. Johansson MH, Hoglund P. The dynamics of natural killer cell tolerance. Semin Cancer Biol. 2006;16:393-403.
136. Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol Rev. 2006;214:130-142.
137. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 2006;214:73-91.
138. Borrego F, Masilamani M, Marusina AI, Tang X, Coligan JE. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol Res. 2006;35:263-278.
139. Boehm T. Quality control in self/nonself discrimination. Cell. 2006;125:845-858.
140. Kloepper JE, Tiede S, Brinckmann J, et al. Immunophenotyping of the human bulge region: the quest to define useful in situ markers for human epithelial hair follicle stem cells and their niche. Exp Dermatol. 2008;17:592-609.
141. Rosenblum MD, Olasz EB, Yancey KB, et al. Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissuespecific immune tolerance? J Invest Dermatol. 2004;123:880-887.
142. Tiede S, Koop N, Kloepper JE, Fassler R, Paus R. Nonviral in situ green fluorescent protein labeling and culture of primary, adult human hair follicle epithelial progenitor cells. Stem Cells. 2009;27:2793-2803.
143. Copland DA, Calder CJ, Raveney BJ, et al. Monoclonal antibodymediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol. 2007;171:580-588.
144. Norris DA. How close are we to solving the puzzle?-review of the Alopecia Areata Research Workshop. J Investig Dermatol Symp Proc. 2003;8:222-225.
145. Whitsett CF, Stulting RD. The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Vis Sci. 1984;25:519-524.
146. Barez S, Boumpas DT, Percopo CM, Anastassiou ED, Hooks JJ, Detrick B. Modulation of major histocompatibility complex class 1 genes in human retinoblastoma cells by interferons. Invest Ophthalmol Vis Sci. 1993;34:2613-2621.
147. Ruckert R, Hofmann U, van der Veen C, Bulfone-Paus S, Paus R. MHC class I expression in murine skin: developmentally controlled and strikingly restricted intraepithelial expression during hair follicle morphogenesis and cycling, and response to cytokine treatment in vivo. J Invest Dermatol. 1998;111:25-30.
148. Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol. 2006;27: 32-39.
149. Arck PC, Handjiski B, Hagen E, Joachim R, Klapp BF, Paus R. Indications for a 'brain-hair follicle axis (BHA)': inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P. FASEB J. 2001;15:2536-2538.
150. Botchkarev VA, Botchkareva NV, Peters EM, Paus R. Epithelial growth control by neurotrophins: leads and lessons from the hair follicle. Prog Brain Res. 2004;146:493-513.
151. Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol. 2007;265-266:143-149.
152. Arck PC, Handjiski B, Peters EM, et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am J Pathol. 2003;162:803-814.
153. Arck PC, Handjiski B, Kuhlmei A, et al. Mast cell deficient and neurokinin-1 receptor knockout mice are protected from stressinduced hair growth inhibition. J Mol Med. 2005;83:386-396.
154. Paus R, Arck P, Tiede S. (Neuro-)endocrinology of epithelial hair follicle stem cells. Mol Cell Endocrinol. 2008;288:38-51.
155. Peters EM, Arck PC, Paus R. Hair growth inhibition by psychoemotional stress: a mouse model for neural mechanisms in hair growth control. Exp Dermatol. 2006;15:1-13.
156. Paus R. A neuroendocrinological perspective on human hair follicle pigmentation. Pigment Cell Melanoma Res. 2011;24:89-106.
157. Joachim RA, Kuhlmei A, Dinh QT, et al. Neuronal plasticity of the "brain-skin connection": stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factordependent pathways. J Mol Med. 2007;85:1369-1378.
158. Peters EM, Handjiski B, Kuhlmei A, et al. Neurogenic inflammation in stress-induced termination of murine hair growth is promoted by nerve growth factor. Am J Pathol. 2004;165:259-271.
159. Siebenhaar F, Sharov AA, Peters EM, et al. Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (alopecia areata). J Invest Dermatol. 2007;127: 1489-1497.
160. Kloepper JE, Hendrix S, Bodo E, et al. Functional role of beta 1 integrin-mediated signalling in the human hair follicle. Exp Cell Res. 2008;314:498-508.
161. Philpott M, Green MR, Kealey T. Studies on the biochemistry and morphology of freshly isolated and maintained rat hair follicles. J Cell Sci. 1989;93:409-418.
162. Philpott MP, Green MR, Kealey T. Human hair growth in vitro. J Cell Sci. 1990;97:463-471.
163. Botchkarev VA, Botchkareva NV, Slominski A, Roloff B, Luger T, Paus R. Developmentally regulated expression of alpha-MSH and MC-1 receptor in C57BL/6 mouse skin suggests functions beyond pigmentation. Ann N Y Acad Sci. 1999;885:433-439.
164. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000;80:979-1020.
165. Carrim ZI, Ahmed TY, Taguri AH. The relationship between stress and acute anterior uveitis. Acta Ophthalmol Scand. 2006;84:795-798.
166. Tiede S, Kloepper JE, Bodo E, Tiwari S, Kruse C, Paus R. Hair follicle stem cells: walking the maze. Eur J Cell Biol. 2007;86: 355-376.
167. Gutierrez-Rivera A, Pavon-Rodriguez A, Jimenez-Acosta F, et al. Functional characterization of highly adherent CD34+ keratinocytes isolated from human skin. Exp Dermatol. 2010;19:685-688.
168. Ohyama M, Zheng Y, Paus R, Stenn KS. The mesenchymal component of hair follicle neogenesis: background, methods and molecular characterization. Exp Dermatol. 2010;19:89-99.
169. Biernaskie J. Human hair follicles: "bulging" with neural crest-like stem cells. J Invest Dermatol. 2010;130:1202-1204.
170. Tiede S, Kloepper JE, Ernst N, Poeggeler B, Kruse C, Paus R. Nestin in human skin: exclusive expression in intramesenchymal skin compartments and regulation by leptin. J Invest Dermatol. 2009;129:2711-2720.
171. Blazejewska EA, Schlotzer-Schrehardt U, Zenkel M, et al. Corneal limbal microenvironment can induce transdifferentiation of hair follicle stem cells into corneal epithelial-like cells. Stem Cells. 2009;27:642-652.
172. Yang K, Jiang Z, Wang D, Lian X, Yang T. Corneal epithelial-like transdifferentiation of hair follicle stem cells is mediated by pax6 and beta-catenin/Lef-1. Cell Biol Int. 2009;33:861-866.
173. Meyer-Blazejewska EA, Call MK, Yamanaka O, et al. From hair to cornea: towards the therapeutic use of hair follicle-derived stem cells in the treatment of limbal stem cell deficiency. Stem Cells. 2011;29:57-66.
174. Tiede S, Bohm K, Meier N, Funk W, Paus R. Endocrine controls of primary adult human stem cell biology: thyroid hormones stimulate keratin 15 expression, apoptosis, and differentiation in human hair follicle epithelial stem cells in situ and in vitro. Eur J Cell Biol. 2010;89:769-777.
175. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Coexpression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun. 2007;364: 778-782.
176. Lee E, Maclaren RE. Sources of retinal pigment epithelium (RPE) for replacement therapy. Br J Ophthalmol. 2011;445-449.